VerifiedFact Checked
Mounjaro or Wegovy: Which is better?

Mounjaro or Wegovy: Which is better?

Mounjaro and Wegovy are two popular weight loss drugs. Both drugs are more effective than exercise and diet alone, but of the two, which is better?

In this guide, we’ll compare the effectiveness, cost and benefits to help you decide which treatment is most suitable for you.

Alexandra Cristina Cowell
Medically reviewed by
Alexandra Cristina Cowell, Writer & Clinical Content Reviewer
Go to
Reviewed on Mar 05, 2025. by Dr Alexandra Cristina Cowell Writer & Clinical Content Reviewer Registered with GPhC (No. 2241935) Next review due on Mar 05, 2028.
Alexandra Cristina

Last updated on Mar 04, 2025.

Was this article useful?
A side-by-side comparison of Wegovy (semaglutide) and Mounjaro (tirzepatide) weight loss injections.
*Annual costs typically range between £2,500 and £3,800 depending on your prescribed maintenance dose.
A side-by-side comparison of Wegovy (semaglutide) and Mounjaro (tirzepatide) weight loss injections.
*Annual costs typically range between £2,500 and £3,800 depending on your prescribed maintenance dose.

Summary:

  • Mounjaro achieved approximately 15% weight loss by month 12, compared to 8% with Wegovy.
  • Annual costs are lower for Mounjaro (£3,300) than Wegovy (£4,200), offering better value.
  • Both drugs cause side effects like nausea and vomiting.
  • Mounjaro reduces oral contraceptive effectiveness, while Wegovy is safe with all contraception types.

How do Wegovy and Mounjaro work?

Wegovy and Mounjaro are two weight loss injections in the category of drugs called GLP-1 receptor agonists. Wegovy contains semaglutide, which targets the GLP-1 receptors, while Mounjaro contains tirzepatide, which targets GLP-1 and GIP receptors.

Mode of action

Semaglutide mimics GLP-1, a hormone that’s naturally released after meals. It promotes feelings of fullness, slows down digestion and reduces your cravings. This regulates your appetite and curbs feelings of hunger.

Tirzepatide mimics GLP-1 and GIP, two hormones that are released after meals. Like semaglutide, it induces satiety, slows digestion and reduces food cravings. The addition of GIP enhances the weight loss effects, making tirzepatide more effective than semaglutide for some users.

Both treatments target GLP-1 receptors, with Mounjaro also targeting GIP receptors. As a result, both increase feelings of fullness, slow digestion and reduce hunger.

How they’re administered

Wegovy and Mounjaro are injected weekly under the skin in your stomach, thigh or upper arm, on the same day around the same time. The dose increases every four weeks until you reach the maintenance dose.

  • Wegovy is available in six doses: 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, and 7.2mg (maintenance dose).
  • Mounjaro is available in six doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg (maintenance dose).

Some people might choose to remain on a lower dose for longer than four weeks because of the side effects or higher costs that come with higher doses. Staying at the lower dose until the side effects become manageable can make the weight loss journey more comfortable. Additionally, as the dose increases, the cost of one pen also increases, so you might decide to wait until you’re financially stable before moving up. While remaining on a lower dose might slow your weight loss progress, it can still deliver results.

For Mounjaro, clinicians might recommend a 10mg maintenance dose instead of the typical 15mg. The difference in weight loss between the two doses is minimal, but the 10mg dose carries a lower risk of side effects and is significantly cheaper.

Which is the most effective for weight loss?

Multiple studies have shown the effectiveness of both Wegovy and Mounjaro for weight loss. Below is a summary of their results.

Effectiveness of Wegovy

In one study with 1961 patients taking 2.4mg semaglutide, the mean weight loss achieved was 14.1% by week 68, compared to 2.4% in the placebo group. The results found:  

  • 86.4% of participants achieved 5% or more weight loss
  • 69.1% of participants achieved 10% or more weight loss
  • 50.5% of participants achieved 15% or more weight loss

These findings were similar to another study with 175 patients with overweight or obesity. The mean weight loss achieved by week 26 was 10.9% (around 12.3kg). The findings included:   

  • 87.3% achieved a weight loss of 5%
  • 54.9% achieved a weight loss of 10%, 
  • 23.5% achieved a weight loss of 15% 
  • 7.8% achieved a weight loss of 20% or more. 

The study also highlighted that higher doses (1.7mg and 2.4mg) resulted in more weight loss than the lower doses (0.25mg, 0.5mg, 1mg). Participants on the higher dose achieved a mean weight loss of 12.1% compared to 9.2% for those receiving lower doses. Other benefits included better cardiovascular health, improvement in blood sugar and reduced risk of kidney disease.

The new 7.2mg dose (STEP UP trial)

For patients who plateau on the standard 2.4mg dose, the 7.2mg dose offers extra weight loss support. In the 72-week STEP UP trial, patients taking 7.2mg achieved an average weight loss of around 20.7% to 21%, with nearly half of participants losing 20% or more of their starting body weight. This brings Wegovy’s top-end efficacy virtually neck-and-neck with Mounjaro’s maximum 15mg dose.

However, stopping treatment with semaglutide often led to weight gain. In a study, 327 patients lost an average of 17.3% of their body weight over 68 weeks, but by week 120, they regained an average of 11.6% of that weight. This shows the importance of continued treatment and adhering to lifestyle changes. 

Effectiveness of Mounjaro

In a study with 2539 participants, the mean weight loss achieved by week 72 using Mounjaro was:

  • 15.0% with 5mg 
  • 19.5% with 10mg 
  • 20.9% with 15mg 
  • 3.1% with placebo 

Aside from the weight loss benefits, participants using tirzepatide showed improvements in blood pressure, insulin sensitivity, and cholesterol levels. Additionally, by week 72, most pre-diabetic participants (95%) had normal blood sugar levels.   

As previously mentioned, the clinician may recommend staying on a 10mg maintenance dose instead of 15mg due to similar effectiveness and cost benefits. The results prove there’s little difference in weight loss achieved with 10mg compared to 15mg.

Similar to semaglutide, stopping tirzepatide commonly led to weight regain. A study of 670 participants who achieved an average weight reduction of 20.9% by week 36. Half of these individuals continued treatment, while the other half received a placebo. Upon follow-up at week 88, patients who continued taking tirzepatide lost an additional 5.5%, whereas those receiving the placebo experienced a 14% weight gain.   

How does Wegovy compare with Mounjaro?

A comparative study found tirzepatide (Mounjaro) to be more effective than semaglutide (Wegovy) in a trial consisting of 41,222 participants. Of these, 32,029 were treated with semaglutide, while 9,193 received tirzepatide. The mean weight loss achieved with each treatment was as follows:   

  • After 3 months: 5.9% for tirzepatide compared to 3.6% for semaglutide.
  • After 6 months: 10.1% for tirzepatide compared to 5.8% for semaglutide.
  • After 12 months: 15.3% for tirzepatide compared to 8.3% for semaglutide.

At entry and intermediate maintenance doses, Mounjaro generally leads to faster and greater weight loss due to its dual GLP-1/GIP action. But at their highest respective doses (Wegovy 7.2mg vs Mounjaro 15mg), both treatments deliver comparable results of around 21% average body weight loss.

Which has the fewest side effects?

Wegovy and Mounjaro carry the risk of side effects, with gastrointestinal side effects being the most common due to GLP-1 receptor agonists’ effect on stomach digestion. The most common side effects reported include: 

  • Nausea
  • Vomiting 
  • Diarrhoea
  • Fatigue 
  • Abdominal pain

While you may experience other side effects, these are the most common ones. For the full list of side effects, always check the patient leaflet. 

To reduce the risk of side effects, consider gradually increasing your dose to allow your body to adjust to the treatment. Alternatively, you can remain on a lower dose until the side effects become manageable. It may also help to avoid fatty or greasy foods and stick to simple, bland options to reduce the risk of nausea and vomiting. Eating small meals more frequently can also aid digestion and relieve symptoms like nausea and abdominal pain.

If the side effects become unmanageable, switching to another weight loss treatment might help. Everyone reacts differently to medications, so try finding one that works best for you. If you’re unsure what to choose, our clinicians are on hand to help.

Which is more cost-effective?

The cost of both Wegovy and Mounjaro works on a tiered system: the introductory doses you take at the start of your journey are cheaper, while the higher maintenance doses cost more.

Because pharmacy prices and manufacturer costs fluctuate, exact annual costs will vary depending on your specific treatment plan, current promotions and the maintenance dose you ultimately settle on.

Cost of Wegovy

One Wegovy pen contains four doses, so each pen lasts four weeks.

  • Starter doses (0.25mg, 0.5mg and 1mg): These are typically the most affordable, starting from around £150 a month.
  • Standard maintenance (1.7mg and 2.4mg): Most patients stabilise here. Staying on 1.7mg or 2.4mg typically places your annual cost between £2,400 and £3,200.
  • High-dose maintenance (7.2mg): For people who tolerate 2.4mg but plateau before hitting their target weight, the 7.2mg dose provides an extra push. Because this is a higher-strength formulation, pens typically range from £250 to £340+ per month, which can bring annual treatment costs closer to £3,600-£4,200.

Cost of Mounjaro

Each Mounjaro pen contains four weekly doses, with prices stepping up across its six strengths (2.5mg to 15mg):

  • Starter doses (2.5mg and 5mg): Priced comparably to Wegovy’s starter pens, usually starting around £140-£170 per month.
  • Intermediate maintenance (7.5mg and 10mg): Many prescribers recommend remaining on the 10mg dose long-term. Clinical trials show minimal difference in weight reduction between 10mg and 15mg, but staying at 10mg keeps annual costs around £2,800-£3,200 while minimising side effects.
  • Maximum maintenance (12.5mg and 15mg): Titrating to the top doses increases monthly costs to around £280-£320+, bringing full-year treatment to around £3,400-£3,800.

The verdict on cost

Of the two treatments, there’s no clear cut ‘cheaper’ option:

  • At standard maintenance tiers (Wegovy 2.4mg vs Mounjaro 10mg), monthly and annual costs are roughly equivalent (usually averaging £200-£260 per month across registered UK providers).
  • At maximum efficacy tiers (Wegovy 7.2mg vs Mounjaro 15mg), both treatments deliver top-end results (~21% average weight loss) at comparable premium price points.
  • Discussing your financial comfort with your prescriber is really important. Staying at the lowest dose that works for you is the most reliable way to keep your treatment affordable.

(Note: Pricing ranges reflect UK private prescription estimates based on typical titration schedules. Individual costs vary depending on personal dosage needs, provider dispensing fees and active promotions. Check our consultation page for live pricing.)

Other costs to keep in mind

It’s recommended to exercise at least 150 minutes a week while using Wegovy and Mounjaro. This can be as simple as walking, running, or following a home workout. But if you choose to go to the gym, this will add to your monthly expenses.

However, you might save on your food bill as it's recommended to follow a calorie deficit diet. This means you're less likely to spend on junk food or weekly takeaways.

How do Wegovy and Mounjaro interact with other medicines?

When Wegovy and Mounjaro are used alongside diabetes medication, they can increase the risk of hypoglycaemia (low blood sugar). This is because these medications stimulate insulin release, lowering blood sugar levels. 

Diabetes medications such as insulin or sulfonylureas (e.g. gliclazide) may require dose adjustments, but they don’t need to be avoided entirely. Your clinician will make sure to closely monitor your blood sugar.

Tirzepatide may affect the absorption of Digoxin (used for heart conditions) and Warfarin (a blood thinner), which could require dose adjustments.   

Semaglutide can interact with Acenocoumarol (a blood thinner) by reducing its effectiveness and may slightly increase exposure to Levothyroxine (used for thyroid conditions). These interactions are manageable with monitoring and dose adjustments.   

It’s important to inform your clinician about any medication you are taking. For the full list of interactions, read the patient leaflet. 

Both drugs share a similar interaction profile, especially concerning increased hypoglycemia risk with other antidiabetic treatments.

Can Wegovy and Mounjaro be used alongside contraception?

Wegovy can be used alongside all types of contraceptives including oral hormonal contraception. However, it’s important to know that side effects like vomiting may affect how well oral contraceptives work.

Mounjaro can decrease the effectiveness of oral contraceptives. Oral hormonal contraceptives are digested in the stomach and absorbed into the bloodstream, but the Mounjaros effect to delay stomach emptying can reduce the absorption of oral contraceptives by as much as 55-66%. Therefore, you should avoid using oral contraceptives during initiation with Mounjaro and for four weeks after each dose escalation. Or use an additional barrier method, like condoms, for added protection.

Non-oral and non-hormonal contraceptives aren’t affected by Mounjaro like patches, IUS, or injections, as they are absorbed directly into the bloodstream or vaginal tissue and don’t require digestion. Non-hormonal contraceptives like copper IUD, don’t require absorption and aren’t affected by Mounjaro. For more information, check our guide on Mounjaro and contraception.

All types of contraceptives can be used with Wegovy, but oral contraceptives should be avoided with Mounjaro.

Reference Popover #ref1
Reference Popover #ref2
Reference Popover #ref3
Reference Popover #ref4
Reference Popover #ref5
Reference Popover #ref6
Reference Popover #ref7
Reference Popover #ref8
Reference Popover #ref9
Reference Popover #ref10

How we source info.

When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.

Tell us what you want to hear.

Have a subject you’d like us to cover in a future article? Let us know.

Give us the inbox treatment.

We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.

Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.